Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 147.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,325 shares of the company’s stock after purchasing an additional 44,332 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.06% of Apellis Pharmaceuticals worth $1,625,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in APLS. EverSource Wealth Advisors LLC grew its holdings in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the period. Signaturefd LLC increased its holdings in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Apellis Pharmaceuticals in the 4th quarter worth $83,000. US Bancorp DE raised its position in Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after acquiring an additional 1,327 shares during the period. Finally, Covestor Ltd lifted its holdings in Apellis Pharmaceuticals by 1,819.2% during the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock valued at $127,000 after purchasing an additional 3,784 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $17.76 on Wednesday. The firm has a market cap of $2.23 billion, a PE ratio of -9.92 and a beta of 0.68. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $42.47. The business’s fifty day simple moving average is $18.27 and its 200-day simple moving average is $24.98.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the previous year, the company earned ($0.54) EPS. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. Equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wedbush cut their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Royal Bank Of Canada lowered their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group reduced their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Wells Fargo & Company raised their target price on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a research report on Monday, June 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.05.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).